Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Parkinson disease"" wg kryterium: Temat


Tytuł :
Hypoxia-inducible factor 1 alpha and nuclear-related receptor 1 as targets for neuroprotection by albendazole in a rat rotenone model of Parkinson's disease.
Autorzy :
Kandil EA; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Sayed RH; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Ahmed LA; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Abd El Fattah MA; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
El-Sayeh BM; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Pokaż więcej
Źródło :
Clinical and experimental pharmacology & physiology [Clin Exp Pharmacol Physiol] 2019 Dec; Vol. 46 (12), pp. 1141-1150. Date of Electronic Publication: 2019 Sep 09.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Wiley-Blackwell Country of Publication: Australia NLM ID: 0425076 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1440-1681 (Electronic) Linking ISSN: 03051870 NLM ISO Abbreviation: Clin. Exp. Pharmacol. Physiol. Subsets: MEDLINE
MeSH Terms :
Parkinson Disease*/drug therapy
Parkinson Disease*/genetics
Parkinson Disease*/pathology
Albendazole/*pharmacology
Hypoxia-Inducible Factor 1, alpha Subunit/*genetics
Neuroprotection/*drug effects
Neuroprotection/*genetics
Nuclear Receptor Subfamily 4, Group A, Member 2/*genetics
Albendazole/therapeutic use ; Animals ; Behavior, Animal/drug effects ; Cell Death/drug effects ; Cell Death/genetics ; Cell Survival/drug effects ; Cell Survival/genetics ; Disease Models, Animal ; Dopaminergic Neurons/drug effects ; Dopaminergic Neurons/physiology ; Gene Expression Regulation/drug effects ; Hypoxia-Inducible Factor 1, alpha Subunit/metabolism ; Male ; Molecular Targeted Therapy ; Neuroprotective Agents/pharmacology ; Neuroprotective Agents/therapeutic use ; Nuclear Receptor Subfamily 4, Group A, Member 2/metabolism ; Parkinson Disease, Secondary/chemically induced ; Parkinson Disease, Secondary/drug therapy ; Parkinson Disease, Secondary/genetics ; Parkinson Disease, Secondary/pathology ; Rats ; Rats, Wistar ; Rotenone
Czasopismo naukowe
Tytuł :
Can the 2019 Novel Coronavirus Cause Parkinson's Disease?
Autorzy :
Achbani A; Laboratory of Cell Biology and Molecular Genetics, Department of Biology, Faculty of Sciences, University Ibn Zohr, Agadir, Morocco.; High Institute of Nursing Professions and Technical Health, Agadir, Morocco.
Sine H; Laboratory of Cell Biology and Molecular Genetics, Department of Biology, Faculty of Sciences, University Ibn Zohr, Agadir, Morocco.; Medical Biology, Human and Experimental Pathology and Environment, Faculty of Medicine and Pharmacy of Rabat, MOHAMED V University of Rabat, Rabat, Morocco.
Naciri A; High Institute of Nursing Professions and Technical Health, Laâyoune, Morocco.
Baba MA; High Institute of Nursing Professions and Technical Health, Agadir, Morocco.
Kharbach A; High Institute of Nursing Professions and Technical Health, Agadir, Morocco.; High Institute of Nursing Professions and Technical Health, Laâyoune, Morocco.
Bouchriti Y; Laboratory of Cell Biology and Molecular Genetics, Department of Biology, Faculty of Sciences, University Ibn Zohr, Agadir, Morocco.
Nejmeddine M; Laboratory of Biostatistics, Clinical Research and Epidemiology (LBRCE), Faculty of Medicine and Pharmacy of Rabat, MOHAMED V University of Rabat, Rabat, Morocco.
Pokaż więcej
Źródło :
Movement disorders : official journal of the Movement Disorder Society [Mov Disord] 2020 Jul; Vol. 35 (7), pp. 1102-1103. Date of Electronic Publication: 2020 Jun 16.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
Journal Info :
Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8610688 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1531-8257 (Electronic) Linking ISSN: 08853185 NLM ISO Abbreviation: Mov. Disord. Subsets: MEDLINE
MeSH Terms :
Coronavirus Infections/*immunology
Inflammation/*immunology
Parkinson Disease, Postencephalitic/*immunology
Pneumonia, Viral/*immunology
Betacoronavirus ; Coronavirus Infections/complications ; Humans ; Pandemics ; Parkinson Disease/etiology ; Parkinson Disease/immunology ; Parkinson Disease/virology ; Parkinson Disease, Postencephalitic/etiology ; Parkinson Disease, Postencephalitic/virology ; Pneumonia, Viral/complications ; Synucleinopathies/immunology ; Synucleinopathies/virology
SCR Disease Name :
COVID-19
SCR Organism :
severe acute respiratory syndrome coronavirus 2
Raport
Tytuł :
A Post-COVID-19 Parkinsonism in the Future?
Autorzy :
Boika AV; Department of Neurology and Neurosurgery, Belarusian Medical Academy of Post-Graduate Education, Minsk, Belarus.
Pokaż więcej
Źródło :
Movement disorders : official journal of the Movement Disorder Society [Mov Disord] 2020 Jul; Vol. 35 (7), pp. 1094. Date of Electronic Publication: 2020 May 21.
Typ publikacji :
Letter
Journal Info :
Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8610688 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1531-8257 (Electronic) Linking ISSN: 08853185 NLM ISO Abbreviation: Mov. Disord. Subsets: MEDLINE
MeSH Terms :
Coronavirus Infections/*epidemiology
Parkinson Disease/*epidemiology
Pneumonia, Viral/*epidemiology
Betacoronavirus ; Humans ; Pandemics ; Parkinson Disease, Postencephalitic ; Parkinsonian Disorders/epidemiology
SCR Disease Name :
COVID-19
SCR Organism :
severe acute respiratory syndrome coronavirus 2
Opinia redakcyjna
Tytuł :
In vivo detection of metabolic changes in the striatum of proteasomal inhibition-induced Parkinson's disease in rats using proton MR spectroscopy at 9.4 T.
Autorzy :
Yang Y; Department of Neurosurgery, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, Anhui, P.R. China.
Qian J; High Magnetic Field Laboratory, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, P.R. China.; Hefei Cancer Hospital, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, P.R.China.
Mei J; Department of Neurosurgery, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, Anhui, P.R. China.
Zhong K; High Magnetic Field Laboratory, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, P.R. China.
Niu C; Department of Neurosurgery, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, Anhui, P.R. China.; Anhui Provincial Key Laboratory of Brain Function and Brain Disease, Hefei, Anhui, P.R. China.
Pokaż więcej
Źródło :
The International journal of neuroscience [Int J Neurosci] 2020 Feb; Vol. 130 (2), pp. 153-160. Date of Electronic Publication: 2019 Oct 02.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Informa Healthcare Country of Publication: England NLM ID: 0270707 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1563-5279 (Electronic) Linking ISSN: 00207454 NLM ISO Abbreviation: Int J Neurosci Subsets: MEDLINE
MeSH Terms :
Corpus Striatum/*metabolism
Parkinson Disease/*metabolism
Protease Inhibitors/*pharmacology
Acetylcysteine/analogs & derivatives ; Acetylcysteine/pharmacology ; Animals ; Corpus Striatum/diagnostic imaging ; Corpus Striatum/drug effects ; Disease Models, Animal ; Male ; Parkinson Disease/diagnostic imaging ; Parkinson Disease, Secondary/chemically induced ; Parkinson Disease, Secondary/metabolism ; Proton Magnetic Resonance Spectroscopy ; Rats ; Rats, Sprague-Dawley
Czasopismo naukowe
Tytuł :
Association Between Motor Subtype and Visuospatial and Executive Function in Mild-Moderate Parkinson Disease.
Autorzy :
Lally H; Emory College of Arts and Sciences, Atlanta, Georgia.
Hart AR; Department of Medicine, Division of General Medicine and Geriatrics, Emory University School of Medicine, Atlanta, Georgia.
Bay AA; Department of Medicine, Division of General Medicine and Geriatrics, Emory University School of Medicine, Atlanta, Georgia.
Kim C; Emory University Rollins School of Public Health, Atlanta, Georgia.
Wolf SL; Department of Medicine, Division of General Medicine and Geriatrics, Emory University School of Medicine, Atlanta, Georgia; Department of Rehabilitation Medicine, Division of Physical Therapy, Emory University School of Medicine, Atlanta, Georgia; Department of Cell Biology, Emory University School of Medicine, Atlanta, Georgia; Atlanta VA Center for Visual and Neurocognitive Rehabilitation, Decatur, Georgia.
Hackney ME; Department of Medicine, Division of General Medicine and Geriatrics, Emory University School of Medicine, Atlanta, Georgia; Department of Rehabilitation Medicine, Division of Physical Therapy, Emory University School of Medicine, Atlanta, Georgia; Atlanta VA Center for Visual and Neurocognitive Rehabilitation, Decatur, Georgia. Electronic address: .
Pokaż więcej
Źródło :
Archives of physical medicine and rehabilitation [Arch Phys Med Rehabil] 2020 Sep; Vol. 101 (9), pp. 1580-1589. Date of Electronic Publication: 2020 Jun 13.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
Journal Info :
Publisher: W.B. Saunders Country of Publication: United States NLM ID: 2985158R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-821X (Electronic) Linking ISSN: 00039993 NLM ISO Abbreviation: Arch Phys Med Rehabil Subsets: Core Clinical (AIM); MEDLINE
MeSH Terms :
Parkinson Disease/*classification
Parkinson Disease/*physiopathology
Aged ; Agnosia/physiopathology ; Antiparkinson Agents/therapeutic use ; Cognition Disorders/physiopathology ; Executive Function/physiology ; Female ; Gait Disorders, Neurologic/physiopathology ; Humans ; Male ; Middle Aged ; Neuropsychological Tests ; Parkinson Disease/drug therapy ; Postural Balance/physiology ; Retrospective Studies ; Severity of Illness Index ; Spatial Navigation/physiology
Czasopismo naukowe
Tytuł :
Improved Parkinsons disease motor score in a single-arm open-label trial of febuxostat and inosine.
Autorzy :
Watanabe H; Nagoya University Graduate School of Medicine, Brain and Mind Research Center, Nagoya.; Fujita Health University School of Medicine, Department of Neurology, Toyoake.
Hattori T; Honmachi Clinic, Naka-ku.
Kume A; KUME Clinic, Mizuho-ku, Nagoya.
Misu K; MISU Clinic, Miyoshi.
Ito T; Saishukan Hospital, Kitanagoya, Aichi.
Koike Y; OASIS Clinic, Ushiku, Ibaraki.
Johnson TA; StaGen Co., Ltd., Taito-ku, Tokyo, Japan.
Kamitsuji S; StaGen Co., Ltd., Taito-ku, Tokyo, Japan.
Kamatani N; StaGen Co., Ltd., Taito-ku, Tokyo, Japan.
Sobue G; Nagoya University Graduate School of Medicine, Brain and Mind Research Center, Nagoya.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2020 Aug 28; Vol. 99 (35), pp. e21576.
Typ publikacji :
Clinical Trial; Journal Article; Multicenter Study
Journal Info :
Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN: 1536-5964 (Electronic) Linking ISSN: 00257974 NLM ISO Abbreviation: Medicine (Baltimore) Subsets: Core Clinical (AIM); MEDLINE
MeSH Terms :
Febuxostat/*therapeutic use
Gout Suppressants/*therapeutic use
Inosine/*therapeutic use
Parkinson Disease/*drug therapy
Adenosine Triphosphate/blood ; Administration, Oral ; Aged ; Case-Control Studies ; Drug Therapy, Combination ; Febuxostat/administration & dosage ; Febuxostat/adverse effects ; Female ; Gout Suppressants/administration & dosage ; Gout Suppressants/adverse effects ; Humans ; Hypoxanthine/blood ; Inosine/administration & dosage ; Inosine/adverse effects ; Japan/epidemiology ; Male ; Middle Aged ; Nervous System Diseases/epidemiology ; Parkinson Disease/metabolism ; Parkinson Disease/physiopathology ; Safety ; Treatment Outcome ; Xanthine Dehydrogenase/antagonists & inhibitors
Czasopismo naukowe
Tytuł :
Interpretation of health-related quality of life outcomes in Parkinson's disease from the EARLYSTIM Study.
Autorzy :
Martinez-Martin P; Center for Networked Biomedical Research in Neurodegenerative Diseases (CIBERNED), Carlos III Institute of Health, Madrid, Spain.
Deuschl G; Department of Neurology, UKSH, Kiel Campus Christian-Albrechts-University, Kiel, Germany.
Tonder L; Medtronic, Minneapolis, Minnesota, United States of America.
Schnitzler A; Department of Neurology, Institute of Clinical Neuroscience and Medical Psychology, Heinrich-Heine University Duesseldorf, Duesseldorf, Germany.
Houeto JL; Department of Neurology, CIC-INSERM 1402, CHU of Poitiers, University of Poitiers, Poitiers, France.
Timmermann L; Universitätsklinikum Giessen und Marburg, Marburg Campus, Marburg, Germany.
Rau J; The Coordinating Center for Clinical Trials, Philipps University, Marburg, Germany.
Schade-Brittinger C; The Coordinating Center for Clinical Trials, Philipps University, Marburg, Germany.
Stoker V; Medtronic, Minneapolis, Minnesota, United States of America.
Vidailhet M; Department of Neurology, Sorbonne Université, ICM UMR1127, INSERM &1127, CNRS 7225, Salpêtriere University Hospital, AP-HP, Paris, France.
Krack P; Department of Neurology, University Hospital Bern, University of Bern, Bern, Switzerland.
Pokaż więcej
Corporate Authors :
EARLYSTIM Study Group
Źródło :
PloS one [PLoS One] 2020 Aug 21; Vol. 15 (8), pp. e0237498. Date of Electronic Publication: 2020 Aug 21 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
Journal Info :
Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
MeSH Terms :
Deep Brain Stimulation*
Quality of Life*
Parkinson Disease/*therapy
Activities of Daily Living ; Cohort Studies ; Humans ; Levodopa/therapeutic use ; Middle Aged ; Parkinson Disease/drug therapy ; Parkinson Disease/pathology ; Parkinson Disease/psychology ; Severity of Illness Index ; Treatment Outcome
Czasopismo naukowe
Tytuł :
β-Glucocerebrosidase activity in GBA -linked Parkinson disease: The type of mutation matters.
Autorzy :
Huh YE; From the APDA Center for Advanced Parkinson Research (Y.E.H., J.J.L., Z.L., G.L., K.C., Y.I.K., I.T., M.T.H., C.R.S.) and Precision Neurology Program (Y.E.H., Z.L., G.L., Y.I.K., C.R.S.), Harvard Medical School, and Department of Neurology (Y.E.H., G.L., C.R.S.), Brigham and Women's Hospital, Boston, MA; Department of Neurology (Y.E.H.), CHA Bundang Medical Center, CHA University, Seongnam, Korea; Rare and Neurological Diseases Therapeutic Area (M.S.R.C., S.P.S.), Sanofi, Framingham, MA; School of Medicine (G.L.), Sun Yat-Sen University, Guangzhou, Guangdong, China; and Department of Neurology (J.J.L., A.V., A.L.H., M.A.S., A.Y.H., T.M.H., B.T.H., A.-M.W., S.N.G., J.H.G., C.R.S.), Massachusetts General Hospital, Boston.
Chiang MSR; From the APDA Center for Advanced Parkinson Research (Y.E.H., J.J.L., Z.L., G.L., K.C., Y.I.K., I.T., M.T.H., C.R.S.) and Precision Neurology Program (Y.E.H., Z.L., G.L., Y.I.K., C.R.S.), Harvard Medical School, and Department of Neurology (Y.E.H., G.L., C.R.S.), Brigham and Women's Hospital, Boston, MA; Department of Neurology (Y.E.H.), CHA Bundang Medical Center, CHA University, Seongnam, Korea; Rare and Neurological Diseases Therapeutic Area (M.S.R.C., S.P.S.), Sanofi, Framingham, MA; School of Medicine (G.L.), Sun Yat-Sen University, Guangzhou, Guangdong, China; and Department of Neurology (J.J.L., A.V., A.L.H., M.A.S., A.Y.H., T.M.H., B.T.H., A.-M.W., S.N.G., J.H.G., C.R.S.), Massachusetts General Hospital, Boston.
Locascio JJ; From the APDA Center for Advanced Parkinson Research (Y.E.H., J.J.L., Z.L., G.L., K.C., Y.I.K., I.T., M.T.H., C.R.S.) and Precision Neurology Program (Y.E.H., Z.L., G.L., Y.I.K., C.R.S.), Harvard Medical School, and Department of Neurology (Y.E.H., G.L., C.R.S.), Brigham and Women's Hospital, Boston, MA; Department of Neurology (Y.E.H.), CHA Bundang Medical Center, CHA University, Seongnam, Korea; Rare and Neurological Diseases Therapeutic Area (M.S.R.C., S.P.S.), Sanofi, Framingham, MA; School of Medicine (G.L.), Sun Yat-Sen University, Guangzhou, Guangdong, China; and Department of Neurology (J.J.L., A.V., A.L.H., M.A.S., A.Y.H., T.M.H., B.T.H., A.-M.W., S.N.G., J.H.G., C.R.S.), Massachusetts General Hospital, Boston.
Liao Z; From the APDA Center for Advanced Parkinson Research (Y.E.H., J.J.L., Z.L., G.L., K.C., Y.I.K., I.T., M.T.H., C.R.S.) and Precision Neurology Program (Y.E.H., Z.L., G.L., Y.I.K., C.R.S.), Harvard Medical School, and Department of Neurology (Y.E.H., G.L., C.R.S.), Brigham and Women's Hospital, Boston, MA; Department of Neurology (Y.E.H.), CHA Bundang Medical Center, CHA University, Seongnam, Korea; Rare and Neurological Diseases Therapeutic Area (M.S.R.C., S.P.S.), Sanofi, Framingham, MA; School of Medicine (G.L.), Sun Yat-Sen University, Guangzhou, Guangdong, China; and Department of Neurology (J.J.L., A.V., A.L.H., M.A.S., A.Y.H., T.M.H., B.T.H., A.-M.W., S.N.G., J.H.G., C.R.S.), Massachusetts General Hospital, Boston.
Liu G; From the APDA Center for Advanced Parkinson Research (Y.E.H., J.J.L., Z.L., G.L., K.C., Y.I.K., I.T., M.T.H., C.R.S.) and Precision Neurology Program (Y.E.H., Z.L., G.L., Y.I.K., C.R.S.), Harvard Medical School, and Department of Neurology (Y.E.H., G.L., C.R.S.), Brigham and Women's Hospital, Boston, MA; Department of Neurology (Y.E.H.), CHA Bundang Medical Center, CHA University, Seongnam, Korea; Rare and Neurological Diseases Therapeutic Area (M.S.R.C., S.P.S.), Sanofi, Framingham, MA; School of Medicine (G.L.), Sun Yat-Sen University, Guangzhou, Guangdong, China; and Department of Neurology (J.J.L., A.V., A.L.H., M.A.S., A.Y.H., T.M.H., B.T.H., A.-M.W., S.N.G., J.H.G., C.R.S.), Massachusetts General Hospital, Boston.
Choudhury K; From the APDA Center for Advanced Parkinson Research (Y.E.H., J.J.L., Z.L., G.L., K.C., Y.I.K., I.T., M.T.H., C.R.S.) and Precision Neurology Program (Y.E.H., Z.L., G.L., Y.I.K., C.R.S.), Harvard Medical School, and Department of Neurology (Y.E.H., G.L., C.R.S.), Brigham and Women's Hospital, Boston, MA; Department of Neurology (Y.E.H.), CHA Bundang Medical Center, CHA University, Seongnam, Korea; Rare and Neurological Diseases Therapeutic Area (M.S.R.C., S.P.S.), Sanofi, Framingham, MA; School of Medicine (G.L.), Sun Yat-Sen University, Guangzhou, Guangdong, China; and Department of Neurology (J.J.L., A.V., A.L.H., M.A.S., A.Y.H., T.M.H., B.T.H., A.-M.W., S.N.G., J.H.G., C.R.S.), Massachusetts General Hospital, Boston.
Kuras YI; From the APDA Center for Advanced Parkinson Research (Y.E.H., J.J.L., Z.L., G.L., K.C., Y.I.K., I.T., M.T.H., C.R.S.) and Precision Neurology Program (Y.E.H., Z.L., G.L., Y.I.K., C.R.S.), Harvard Medical School, and Department of Neurology (Y.E.H., G.L., C.R.S.), Brigham and Women's Hospital, Boston, MA; Department of Neurology (Y.E.H.), CHA Bundang Medical Center, CHA University, Seongnam, Korea; Rare and Neurological Diseases Therapeutic Area (M.S.R.C., S.P.S.), Sanofi, Framingham, MA; School of Medicine (G.L.), Sun Yat-Sen University, Guangzhou, Guangdong, China; and Department of Neurology (J.J.L., A.V., A.L.H., M.A.S., A.Y.H., T.M.H., B.T.H., A.-M.W., S.N.G., J.H.G., C.R.S.), Massachusetts General Hospital, Boston.
Tuncali I; From the APDA Center for Advanced Parkinson Research (Y.E.H., J.J.L., Z.L., G.L., K.C., Y.I.K., I.T., M.T.H., C.R.S.) and Precision Neurology Program (Y.E.H., Z.L., G.L., Y.I.K., C.R.S.), Harvard Medical School, and Department of Neurology (Y.E.H., G.L., C.R.S.), Brigham and Women's Hospital, Boston, MA; Department of Neurology (Y.E.H.), CHA Bundang Medical Center, CHA University, Seongnam, Korea; Rare and Neurological Diseases Therapeutic Area (M.S.R.C., S.P.S.), Sanofi, Framingham, MA; School of Medicine (G.L.), Sun Yat-Sen University, Guangzhou, Guangdong, China; and Department of Neurology (J.J.L., A.V., A.L.H., M.A.S., A.Y.H., T.M.H., B.T.H., A.-M.W., S.N.G., J.H.G., C.R.S.), Massachusetts General Hospital, Boston.
Videnovic A; From the APDA Center for Advanced Parkinson Research (Y.E.H., J.J.L., Z.L., G.L., K.C., Y.I.K., I.T., M.T.H., C.R.S.) and Precision Neurology Program (Y.E.H., Z.L., G.L., Y.I.K., C.R.S.), Harvard Medical School, and Department of Neurology (Y.E.H., G.L., C.R.S.), Brigham and Women's Hospital, Boston, MA; Department of Neurology (Y.E.H.), CHA Bundang Medical Center, CHA University, Seongnam, Korea; Rare and Neurological Diseases Therapeutic Area (M.S.R.C., S.P.S.), Sanofi, Framingham, MA; School of Medicine (G.L.), Sun Yat-Sen University, Guangzhou, Guangdong, China; and Department of Neurology (J.J.L., A.V., A.L.H., M.A.S., A.Y.H., T.M.H., B.T.H., A.-M.W., S.N.G., J.H.G., C.R.S.), Massachusetts General Hospital, Boston.
Hunt AL; From the APDA Center for Advanced Parkinson Research (Y.E.H., J.J.L., Z.L., G.L., K.C., Y.I.K., I.T., M.T.H., C.R.S.) and Precision Neurology Program (Y.E.H., Z.L., G.L., Y.I.K., C.R.S.), Harvard Medical School, and Department of Neurology (Y.E.H., G.L., C.R.S.), Brigham and Women's Hospital, Boston, MA; Department of Neurology (Y.E.H.), CHA Bundang Medical Center, CHA University, Seongnam, Korea; Rare and Neurological Diseases Therapeutic Area (M.S.R.C., S.P.S.), Sanofi, Framingham, MA; School of Medicine (G.L.), Sun Yat-Sen University, Guangzhou, Guangdong, China; and Department of Neurology (J.J.L., A.V., A.L.H., M.A.S., A.Y.H., T.M.H., B.T.H., A.-M.W., S.N.G., J.H.G., C.R.S.), Massachusetts General Hospital, Boston.
Schwarzschild MA; From the APDA Center for Advanced Parkinson Research (Y.E.H., J.J.L., Z.L., G.L., K.C., Y.I.K., I.T., M.T.H., C.R.S.) and Precision Neurology Program (Y.E.H., Z.L., G.L., Y.I.K., C.R.S.), Harvard Medical School, and Department of Neurology (Y.E.H., G.L., C.R.S.), Brigham and Women's Hospital, Boston, MA; Department of Neurology (Y.E.H.), CHA Bundang Medical Center, CHA University, Seongnam, Korea; Rare and Neurological Diseases Therapeutic Area (M.S.R.C., S.P.S.), Sanofi, Framingham, MA; School of Medicine (G.L.), Sun Yat-Sen University, Guangzhou, Guangdong, China; and Department of Neurology (J.J.L., A.V., A.L.H., M.A.S., A.Y.H., T.M.H., B.T.H., A.-M.W., S.N.G., J.H.G., C.R.S.), Massachusetts General Hospital, Boston.
Hung AY; From the APDA Center for Advanced Parkinson Research (Y.E.H., J.J.L., Z.L., G.L., K.C., Y.I.K., I.T., M.T.H., C.R.S.) and Precision Neurology Program (Y.E.H., Z.L., G.L., Y.I.K., C.R.S.), Harvard Medical School, and Department of Neurology (Y.E.H., G.L., C.R.S.), Brigham and Women's Hospital, Boston, MA; Department of Neurology (Y.E.H.), CHA Bundang Medical Center, CHA University, Seongnam, Korea; Rare and Neurological Diseases Therapeutic Area (M.S.R.C., S.P.S.), Sanofi, Framingham, MA; School of Medicine (G.L.), Sun Yat-Sen University, Guangzhou, Guangdong, China; and Department of Neurology (J.J.L., A.V., A.L.H., M.A.S., A.Y.H., T.M.H., B.T.H., A.-M.W., S.N.G., J.H.G., C.R.S.), Massachusetts General Hospital, Boston.
Herrington TM; From the APDA Center for Advanced Parkinson Research (Y.E.H., J.J.L., Z.L., G.L., K.C., Y.I.K., I.T., M.T.H., C.R.S.) and Precision Neurology Program (Y.E.H., Z.L., G.L., Y.I.K., C.R.S.), Harvard Medical School, and Department of Neurology (Y.E.H., G.L., C.R.S.), Brigham and Women's Hospital, Boston, MA; Department of Neurology (Y.E.H.), CHA Bundang Medical Center, CHA University, Seongnam, Korea; Rare and Neurological Diseases Therapeutic Area (M.S.R.C., S.P.S.), Sanofi, Framingham, MA; School of Medicine (G.L.), Sun Yat-Sen University, Guangzhou, Guangdong, China; and Department of Neurology (J.J.L., A.V., A.L.H., M.A.S., A.Y.H., T.M.H., B.T.H., A.-M.W., S.N.G., J.H.G., C.R.S.), Massachusetts General Hospital, Boston.
Hayes MT; From the APDA Center for Advanced Parkinson Research (Y.E.H., J.J.L., Z.L., G.L., K.C., Y.I.K., I.T., M.T.H., C.R.S.) and Precision Neurology Program (Y.E.H., Z.L., G.L., Y.I.K., C.R.S.), Harvard Medical School, and Department of Neurology (Y.E.H., G.L., C.R.S.), Brigham and Women's Hospital, Boston, MA; Department of Neurology (Y.E.H.), CHA Bundang Medical Center, CHA University, Seongnam, Korea; Rare and Neurological Diseases Therapeutic Area (M.S.R.C., S.P.S.), Sanofi, Framingham, MA; School of Medicine (G.L.), Sun Yat-Sen University, Guangzhou, Guangdong, China; and Department of Neurology (J.J.L., A.V., A.L.H., M.A.S., A.Y.H., T.M.H., B.T.H., A.-M.W., S.N.G., J.H.G., C.R.S.), Massachusetts General Hospital, Boston.
Hyman BT; From the APDA Center for Advanced Parkinson Research (Y.E.H., J.J.L., Z.L., G.L., K.C., Y.I.K., I.T., M.T.H., C.R.S.) and Precision Neurology Program (Y.E.H., Z.L., G.L., Y.I.K., C.R.S.), Harvard Medical School, and Department of Neurology (Y.E.H., G.L., C.R.S.), Brigham and Women's Hospital, Boston, MA; Department of Neurology (Y.E.H.), CHA Bundang Medical Center, CHA University, Seongnam, Korea; Rare and Neurological Diseases Therapeutic Area (M.S.R.C., S.P.S.), Sanofi, Framingham, MA; School of Medicine (G.L.), Sun Yat-Sen University, Guangzhou, Guangdong, China; and Department of Neurology (J.J.L., A.V., A.L.H., M.A.S., A.Y.H., T.M.H., B.T.H., A.-M.W., S.N.G., J.H.G., C.R.S.), Massachusetts General Hospital, Boston.
Wills AM; From the APDA Center for Advanced Parkinson Research (Y.E.H., J.J.L., Z.L., G.L., K.C., Y.I.K., I.T., M.T.H., C.R.S.) and Precision Neurology Program (Y.E.H., Z.L., G.L., Y.I.K., C.R.S.), Harvard Medical School, and Department of Neurology (Y.E.H., G.L., C.R.S.), Brigham and Women's Hospital, Boston, MA; Department of Neurology (Y.E.H.), CHA Bundang Medical Center, CHA University, Seongnam, Korea; Rare and Neurological Diseases Therapeutic Area (M.S.R.C., S.P.S.), Sanofi, Framingham, MA; School of Medicine (G.L.), Sun Yat-Sen University, Guangzhou, Guangdong, China; and Department of Neurology (J.J.L., A.V., A.L.H., M.A.S., A.Y.H., T.M.H., B.T.H., A.-M.W., S.N.G., J.H.G., C.R.S.), Massachusetts General Hospital, Boston.
Gomperts SN; From the APDA Center for Advanced Parkinson Research (Y.E.H., J.J.L., Z.L., G.L., K.C., Y.I.K., I.T., M.T.H., C.R.S.) and Precision Neurology Program (Y.E.H., Z.L., G.L., Y.I.K., C.R.S.), Harvard Medical School, and Department of Neurology (Y.E.H., G.L., C.R.S.), Brigham and Women's Hospital, Boston, MA; Department of Neurology (Y.E.H.), CHA Bundang Medical Center, CHA University, Seongnam, Korea; Rare and Neurological Diseases Therapeutic Area (M.S.R.C., S.P.S.), Sanofi, Framingham, MA; School of Medicine (G.L.), Sun Yat-Sen University, Guangzhou, Guangdong, China; and Department of Neurology (J.J.L., A.V., A.L.H., M.A.S., A.Y.H., T.M.H., B.T.H., A.-M.W., S.N.G., J.H.G., C.R.S.), Massachusetts General Hospital, Boston.
Growdon JH; From the APDA Center for Advanced Parkinson Research (Y.E.H., J.J.L., Z.L., G.L., K.C., Y.I.K., I.T., M.T.H., C.R.S.) and Precision Neurology Program (Y.E.H., Z.L., G.L., Y.I.K., C.R.S.), Harvard Medical School, and Department of Neurology (Y.E.H., G.L., C.R.S.), Brigham and Women's Hospital, Boston, MA; Department of Neurology (Y.E.H.), CHA Bundang Medical Center, CHA University, Seongnam, Korea; Rare and Neurological Diseases Therapeutic Area (M.S.R.C., S.P.S.), Sanofi, Framingham, MA; School of Medicine (G.L.), Sun Yat-Sen University, Guangzhou, Guangdong, China; and Department of Neurology (J.J.L., A.V., A.L.H., M.A.S., A.Y.H., T.M.H., B.T.H., A.-M.W., S.N.G., J.H.G., C.R.S.), Massachusetts General Hospital, Boston.
Sardi SP; From the APDA Center for Advanced Parkinson Research (Y.E.H., J.J.L., Z.L., G.L., K.C., Y.I.K., I.T., M.T.H., C.R.S.) and Precision Neurology Program (Y.E.H., Z.L., G.L., Y.I.K., C.R.S.), Harvard Medical School, and Department of Neurology (Y.E.H., G.L., C.R.S.), Brigham and Women's Hospital, Boston, MA; Department of Neurology (Y.E.H.), CHA Bundang Medical Center, CHA University, Seongnam, Korea; Rare and Neurological Diseases Therapeutic Area (M.S.R.C., S.P.S.), Sanofi, Framingham, MA; School of Medicine (G.L.), Sun Yat-Sen University, Guangzhou, Guangdong, China; and Department of Neurology (J.J.L., A.V., A.L.H., M.A.S., A.Y.H., T.M.H., B.T.H., A.-M.W., S.N.G., J.H.G., C.R.S.), Massachusetts General Hospital, Boston.
Scherzer CR; From the APDA Center for Advanced Parkinson Research (Y.E.H., J.J.L., Z.L., G.L., K.C., Y.I.K., I.T., M.T.H., C.R.S.) and Precision Neurology Program (Y.E.H., Z.L., G.L., Y.I.K., C.R.S.), Harvard Medical School, and Department of Neurology (Y.E.H., G.L., C.R.S.), Brigham and Women's Hospital, Boston, MA; Department of Neurology (Y.E.H.), CHA Bundang Medical Center, CHA University, Seongnam, Korea; Rare and Neurological Diseases Therapeutic Area (M.S.R.C., S.P.S.), Sanofi, Framingham, MA; School of Medicine (G.L.), Sun Yat-Sen University, Guangzhou, Guangdong, China; and Department of Neurology (J.J.L., A.V., A.L.H., M.A.S., A.Y.H., T.M.H., B.T.H., A.-M.W., S.N.G., J.H.G., C.R.S.), Massachusetts General Hospital, Boston. .
Pokaż więcej
Źródło :
Neurology [Neurology] 2020 Aug 11; Vol. 95 (6), pp. e685-e696. Date of Electronic Publication: 2020 Jun 15.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info :
Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0401060 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1526-632X (Electronic) Linking ISSN: 00283878 NLM ISO Abbreviation: Neurology Subsets: Core Clinical (AIM); MEDLINE
MeSH Terms :
Mutation*
Glucosylceramidase/*genetics
Parkinson Disease/*genetics
Aged ; Aged, 80 and over ; Cognition Disorders/etiology ; Cross-Sectional Studies ; Female ; Follow-Up Studies ; Genetic Association Studies ; Glucosylceramidase/blood ; Humans ; Male ; Middle Aged ; Neurologic Examination ; Parkinson Disease/enzymology ; Parkinson Disease/physiopathology ; Parkinson Disease/psychology ; Quantitative Trait Loci ; Severity of Illness Index
Czasopismo naukowe
Tytuł :
Effects of COVID-19 on Parkinson's Disease Clinical Features: A Community-Based Case-Control Study.
Autorzy :
Cilia R; Fondazione IRCCS Istituto Neurologico Carlo Besta, Department of Clinical Neurosciences, Parkinson and Movement Disorders Unit, Milan, Italy.
Bonvegna S; Fondazione IRCCS Istituto Neurologico Carlo Besta, Department of Clinical Neurosciences, Parkinson and Movement Disorders Unit, Milan, Italy.
Straccia G; Fondazione IRCCS Istituto Neurologico Carlo Besta, Department of Clinical Neurosciences, Parkinson and Movement Disorders Unit, Milan, Italy.; Department of Medical Sciences and Advanced Surgery, University of Campania, Naples, Italy.
Andreasi NG; Fondazione IRCCS Istituto Neurologico Carlo Besta, Department of Clinical Neurosciences, Parkinson and Movement Disorders Unit, Milan, Italy.
Elia AE; Fondazione IRCCS Istituto Neurologico Carlo Besta, Department of Clinical Neurosciences, Parkinson and Movement Disorders Unit, Milan, Italy.
Romito LM; Fondazione IRCCS Istituto Neurologico Carlo Besta, Department of Clinical Neurosciences, Parkinson and Movement Disorders Unit, Milan, Italy.
Devigili G; Fondazione IRCCS Istituto Neurologico Carlo Besta, Department of Clinical Neurosciences, Parkinson and Movement Disorders Unit, Milan, Italy.
Cereda E; Clinical Nutrition and Dietetics Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Eleopra R; Fondazione IRCCS Istituto Neurologico Carlo Besta, Department of Clinical Neurosciences, Parkinson and Movement Disorders Unit, Milan, Italy.
Pokaż więcej
Źródło :
Movement disorders : official journal of the Movement Disorder Society [Mov Disord] 2020 Aug; Vol. 35 (8), pp. 1287-1292. Date of Electronic Publication: 2020 Jun 11.
Typ publikacji :
Journal Article; Review
Journal Info :
Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8610688 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1531-8257 (Electronic) Linking ISSN: 08853185 NLM ISO Abbreviation: Mov. Disord. Subsets: MEDLINE
MeSH Terms :
Betacoronavirus/*pathogenicity
Coronavirus Infections/*complications
Coronavirus Infections/*virology
Parkinson Disease/*physiopathology
Pneumonia, Viral/*complications
Pneumonia, Viral/*virology
Case-Control Studies ; Cognition/physiology ; Cognition Disorders/virology ; Depression/psychology ; Depression/virology ; Humans ; Pandemics ; Parkinson Disease/complications ; Parkinson Disease/virology
SCR Disease Name :
COVID-19
SCR Organism :
severe acute respiratory syndrome coronavirus 2
Czasopismo naukowe
Tytuł :
COVID-19 infection may increase the risk of parkinsonism - Remember the Spanish flu?
Autorzy :
Eldeeb MA; Department of Neurology and Neurosurgery, Montreal Neurological Institute McGill University, Montreal, Quebec, Canada. Electronic address: .
Hussain FS; Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Siddiqi ZA; Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Pokaż więcej
Źródło :
Cytokine & growth factor reviews [Cytokine Growth Factor Rev] 2020 Aug; Vol. 54, pp. 6-7. Date of Electronic Publication: 2020 Jun 07.
Typ publikacji :
Historical Article; Letter
Journal Info :
Publisher: Elsevier Science Country of Publication: England NLM ID: 9612306 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0305 (Electronic) Linking ISSN: 13596101 NLM ISO Abbreviation: Cytokine Growth Factor Rev. Subsets: MEDLINE
MeSH Terms :
Coronavirus Infections/*pathology
Cytokine Release Syndrome/*pathology
Influenza, Human/*pathology
Parkinson Disease/*virology
Pneumonia, Viral/*pathology
Betacoronavirus/pathogenicity ; Coronavirus Infections/mortality ; Cytokines/blood ; History, 20th Century ; Humans ; Influenza Pandemic, 1918-1919 ; Influenza, Human/mortality ; Pandemics ; Parkinson Disease/epidemiology ; Parkinson Disease/pathology ; Pneumonia, Viral/mortality
SCR Disease Name :
COVID-19
SCR Organism :
severe acute respiratory syndrome coronavirus 2
Opinia redakcyjna
Tytuł :
Phenomenology and Outcomes of In-Patients With Parkinson's Disease During the Coronavirus Disease 2019 Pandemic.
Autorzy :
Kobylecki C; Department of Neurology, Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Salford, United Kingdom.; Manchester Academic Health Sciences Centre, University of Manchester, Manchester, United Kingdom.
Jones T; Department of Ageing and Complex Medicine, Salford Royal NHS Foundation Trust, Salford, United Kingdom.
Lim CK; Department of Ageing and Complex Medicine, Salford Royal NHS Foundation Trust, Salford, United Kingdom.
Miller C; Department of Neurology, Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Salford, United Kingdom.; Department of Ageing and Complex Medicine, Salford Royal NHS Foundation Trust, Salford, United Kingdom.
Thomson AM; Department of Ageing and Complex Medicine, Salford Royal NHS Foundation Trust, Salford, United Kingdom.
Pokaż więcej
Źródło :
Movement disorders : official journal of the Movement Disorder Society [Mov Disord] 2020 Aug; Vol. 35 (8), pp. 1295-1296. Date of Electronic Publication: 2020 Jul 31.
Typ publikacji :
Letter
Journal Info :
Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8610688 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1531-8257 (Electronic) Linking ISSN: 08853185 NLM ISO Abbreviation: Mov. Disord. Subsets: MEDLINE
MeSH Terms :
Pandemics*
Coronavirus Infections/*complications
Parkinson Disease/*complications
Pneumonia, Viral/*complications
Aged ; Aged, 80 and over ; Coronavirus Infections/mortality ; Coronavirus Infections/therapy ; Dementia/complications ; Female ; Hospital Mortality ; Humans ; Male ; Parkinson Disease/mortality ; Parkinson Disease/therapy ; Pneumonia, Viral/mortality ; Pneumonia, Viral/therapy
SCR Disease Name :
COVID-19
Opinia redakcyjna
Tytuł :
Intranasal insulin ameliorates cognitive impairment in a rat model of Parkinson's disease through Akt/GSK3β signaling pathway.
Autorzy :
Yang L; Department of Neurology, Affiliated Hospital of Qingdao University, Qingdao, China.
Zhang X; Department of Neurology, Affiliated Hospital of Qingdao University, Qingdao, China.
Li S; Department of Neurology, Affiliated Hospital of Qingdao University, Qingdao, China.
Wang H; Department of Neurology, Affiliated Hospital of Qingdao University, Qingdao, China.
Zhang X; Department of Neurology, Affiliated Hospital of Qingdao University, Qingdao, China.
Liu L; Department of Neurology, Affiliated Hospital of Qingdao University, Qingdao, China.
Xie A; Department of Neurology, Affiliated Hospital of Qingdao University, Qingdao, China. Electronic address: .
Pokaż więcej
Źródło :
Life sciences [Life Sci] 2020 Oct 15; Vol. 259, pp. 118159. Date of Electronic Publication: 2020 Aug 04.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Elsevier Country of Publication: Netherlands NLM ID: 0375521 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0631 (Electronic) Linking ISSN: 00243205 NLM ISO Abbreviation: Life Sci Subsets: MEDLINE
MeSH Terms :
Cognitive Dysfunction/*drug therapy
Cognitive Dysfunction/*etiology
Glycogen Synthase Kinase 3 beta/*drug effects
Hypoglycemic Agents/*therapeutic use
Insulin/*therapeutic use
Oncogene Protein v-akt/*drug effects
Parkinson Disease/*complications
Signal Transduction/*drug effects
Administration, Intranasal ; Animals ; Brain/pathology ; Cognitive Dysfunction/psychology ; Dopaminergic Neurons/drug effects ; Dopaminergic Neurons/pathology ; Glycogen Synthase Kinase 3 beta/metabolism ; Hypoglycemic Agents/administration & dosage ; Insulin/administration & dosage ; Male ; Maze Learning/drug effects ; Parkinson Disease/psychology ; Rats ; Rats, Wistar
Czasopismo naukowe
Tytuł :
Developing therapies for Parkinson's disease.
Autorzy :
The Lancet Neurology
Pokaż więcej
Źródło :
The Lancet. Neurology [Lancet Neurol] 2020 Oct; Vol. 19 (10), pp. 797. Date of Electronic Publication: 2020 Sep 16.
Typ publikacji :
Editorial
Journal Info :
Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 101139309 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-4465 (Electronic) Linking ISSN: 14744422 NLM ISO Abbreviation: Lancet Neurol Subsets: MEDLINE
MeSH Terms :
Parkinson Disease/*therapy
Public-Private Sector Partnerships/*trends
Humans ; National Institutes of Health (U.S.)/trends ; Organizations, Nonprofit/trends ; Parkinson Disease/epidemiology ; United States/epidemiology
Opinia redakcyjna
Tytuł :
Studies of deep brain stimulation in Parkinson's disease.
Autorzy :
Vitek JL; Department of Neurology, University of Minnesota School of Medicine, Minneapolis, MN 551113, USA. Electronic address: .
Starr PA; Department of Neurosurgery, University of California San Francisco, San Francisco, CA, USA.
Pokaż więcej
Źródło :
The Lancet. Neurology [Lancet Neurol] 2020 Oct; Vol. 19 (10), pp. 807-808. Date of Electronic Publication: 2020 Sep 16.
Typ publikacji :
Letter; Comment
Journal Info :
Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 101139309 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-4465 (Electronic) Linking ISSN: 14744422 NLM ISO Abbreviation: Lancet Neurol Subsets: MEDLINE
MeSH Terms :
Deep Brain Stimulation*
Parkinson Disease*
Subthalamic Nucleus*
Humans
Opinia redakcyjna
Tytuł :
Striatal dopamine transporters and cognitive function in Parkinson's disease.
Autorzy :
Stögbauer J; Department of Neurology, Saarland University, Homburg/Saar, Germany.
Rosar F; Department of Nuclear Medicine, Saarland University, Homburg/Saar, Germany.
Dillmann U; Department of Neurology, Saarland University, Homburg/Saar, Germany.
Faßbender K; Department of Neurology, Saarland University, Homburg/Saar, Germany.
Ezziddin S; Department of Nuclear Medicine, Saarland University, Homburg/Saar, Germany.
Spiegel J; Department of Neurology, Saarland University, Homburg/Saar, Germany.
Pokaż więcej
Źródło :
Acta neurologica Scandinavica [Acta Neurol Scand] 2020 Oct; Vol. 142 (4), pp. 385-391. Date of Electronic Publication: 2020 Aug 05.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Wiley-Blackwell Country of Publication: Denmark NLM ID: 0370336 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0404 (Electronic) Linking ISSN: 00016314 NLM ISO Abbreviation: Acta Neurol. Scand. Subsets: MEDLINE
MeSH Terms :
Cognition*
Radiopharmaceuticals*
Tomography, Emission-Computed, Single-Photon*
Tropanes*
Corpus Striatum/*diagnostic imaging
Parkinson Disease/*diagnostic imaging
Corpus Striatum/metabolism ; Female ; Humans ; Male ; Parkinson Disease/physiopathology ; Tremor
Czasopismo naukowe
Tytuł :
Re: Home-Based 'Exergaming' Was Safe and Significantly Improved 6-Min Walking Distance in Patients with Prostate Cancer: A Single-Blinded Randomised Controlled Trial.
Autorzy :
Griebling TL
Pokaż więcej
Źródło :
The Journal of urology [J Urol] 2020 Oct; Vol. 204 (4), pp. 858. Date of Electronic Publication: 2020 Jul 23.
Typ publikacji :
Journal Article; Comment
Journal Info :
Publisher: Wolters Kluwer Country of Publication: United States NLM ID: 0376374 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-3792 (Electronic) Linking ISSN: 00225347 NLM ISO Abbreviation: J Urol Subsets: Core Clinical (AIM); MEDLINE
MeSH Terms :
Parkinson Disease*
Prostatic Neoplasms*
Exercise Therapy ; Humans ; Male ; Walking
Czasopismo naukowe
Tytuł :
Obstructive sleep apnea in Parkinson's disease.
Autorzy :
Kawada T; Department of Hygiene and Public Health, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8602, Japan. Electronic address: .
Pokaż więcej
Źródło :
Sleep medicine [Sleep Med] 2020 Oct; Vol. 74, pp. 91. Date of Electronic Publication: 2020 May 21.
Typ publikacji :
Letter; Comment
Journal Info :
Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 100898759 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-5506 (Electronic) Linking ISSN: 13899457 NLM ISO Abbreviation: Sleep Med Subsets: MEDLINE
MeSH Terms :
Parkinson Disease*
Sleep Apnea, Obstructive*
Humans ; Polysomnography
Opinia redakcyjna
Tytuł :
Endosomal Trafficking in Alzheimer's Disease, Parkinson's Disease, and Neuronal Ceroid Lipofuscinosis.
Autorzy :
Qureshi YH; The Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, USA.
Baez P; The Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, USA.
Reitz C; The Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, USA .; The Gertrude H. Sergievsky Center, Columbia University, New York, New York, USA.; Department of Neurology, Columbia University, New York, New York, USA.; Department of Epidemiology, Columbia University, New York, New York, USA.
Pokaż więcej
Źródło :
Molecular and cellular biology [Mol Cell Biol] 2020 Sep 14; Vol. 40 (19). Date of Electronic Publication: 2020 Sep 14 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Review
Journal Info :
Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 8109087 Publication Model: Electronic-Print Cited Medium: Internet ISSN: 1098-5549 (Electronic) Linking ISSN: 02707306 Subsets: MEDLINE
MeSH Terms :
Alzheimer Disease/*metabolism
Endosomes/*metabolism
Neuronal Ceroid-Lipofuscinoses/*genetics
Neuronal Ceroid-Lipofuscinoses/*metabolism
Parkinson Disease/*metabolism
Alzheimer Disease/genetics ; Animals ; Biological Transport ; Humans ; Parkinson Disease/genetics ; Presenilin-1/genetics ; Presenilin-1/metabolism
Czasopismo naukowe
Tytuł :
COVID-19 and selective vulnerability to Parkinson's disease.
Autorzy :
Pavel A; Division of Neurology, Pacific Parkinson's Research Centre, Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, BC V6T2B5, Canada.
Murray DK; Division of Neurology, Pacific Parkinson's Research Centre, Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, BC V6T2B5, Canada.
Stoessl AJ; Division of Neurology, Pacific Parkinson's Research Centre, Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, BC V6T2B5, Canada. Electronic address: .
Pokaż więcej
Źródło :
The Lancet. Neurology [Lancet Neurol] 2020 Sep; Vol. 19 (9), pp. 719.
Typ publikacji :
Letter
Journal Info :
Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 101139309 Publication Model: Print Cited Medium: Internet ISSN: 1474-4465 (Electronic) Linking ISSN: 14744422 NLM ISO Abbreviation: Lancet Neurol Subsets: MEDLINE
MeSH Terms :
Betacoronavirus/*metabolism
Coronavirus Infections/*metabolism
Disease Susceptibility/*metabolism
Parkinson Disease/*metabolism
Pneumonia, Viral/*metabolism
Animals ; Coronavirus Infections/epidemiology ; Disease Susceptibility/epidemiology ; Humans ; Pandemics ; Parkinson Disease/epidemiology ; Phosphorylation/physiology ; Pneumonia, Viral/epidemiology ; alpha-Synuclein/metabolism
SCR Disease Name :
COVID-19
SCR Organism :
severe acute respiratory syndrome coronavirus 2
Opinia redakcyjna
Tytuł :
[Structure and efferences of the substantia nigra pars compacta in Parkinson's disease].
Transliterated Title :
Struktur und Efferenzen der Substantia nigra pars compacta beim idiopathischen Parkinson-Syndrom.
Autorzy :
Urban P; Abteilung für Neurologie, Asklepios Klinik Barmbek.
Falkenburger B; Klinik für Neurologie, Universitätsklinikum Carl Gustav Carus, Dresden.
Jost WH; Parkinson-Klinik Ortenau, Wolfach.
Ransmayr G; Klinik für Neurologie 2, Kepler Universitätsklinikum, Linz/Austria.
Riederer P; Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie, Universitätsklinikum Würzburg.
Winkler C; Krankenhaus Lindenbrunn, Coppenbrügge.
Pokaż więcej
Źródło :
Fortschritte der Neurologie-Psychiatrie [Fortschr Neurol Psychiatr] 2020 Sep; Vol. 88 (9), pp. 591-599. Date of Electronic Publication: 2020 May 12.
Typ publikacji :
Journal Article; Review
Journal Info :
Publisher: Thieme Country of Publication: Germany NLM ID: 8103137 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1439-3522 (Electronic) Linking ISSN: 07204299 NLM ISO Abbreviation: Fortschr Neurol Psychiatr Subsets: MEDLINE
MeSH Terms :
Parkinson Disease*/pathology
Pars Compacta*/pathology
Animals ; Humans
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies